Bronchogen

Overview

Bronchogen is a bioregulator peptide developed in Russia and aimed specifically at bronchial and lung tissue. It belongs to the Khavinson peptide family and is marketed to support respiratory function and encourage regeneration of lung tissue.

Editorial verdict

Bronchogen sits squarely in the Khavinson short-peptide tradition, a body of work that is heavily Russian-sourced and light on independent Western validation. There is exactly one RCT on file, and much of the cited literature is in vitro work on DNA interactions or even plant cells rather than human respiratory outcomes. The effects may be real but are likely subtle, and the evidence base is thin enough that confident claims about respiratory benefit should be treated with caution.

How it works

The peptide (Ala-Asp-Glu-Leu) is proposed to act as a tissue-specific bioregulator. In vitro studies report that it stabilizes DNA, influences gene expression, and can penetrate cell nuclei to interact with DNA and RNA, which is the mechanistic story behind its claimed regenerative effects on bronchial tissue.

Evidence quality

The grade is B+, weighted across 62 peer-reviewed studies (1 RCT, 1 observational, 29 animal, 28 in vitro, 3 reviews). Of 62 classified findings, 45 support, 14 are mixed, and 3 are null. With only a single RCT, the human evidence base is minimal, and the strongest disease-model result comes from rats rather than people.

Who should be cautious

Given how limited the long-term safety data is, and how few human studies exist, anyone with serious respiratory illness should not treat this as a substitute for established medical care.

Community sentiment

Across 4 community reports, discussion is sparse, with 'lung support' the recurring topic.

Studies cited (summarised)

• An in vitro study finding bronchogen raises DNA melting temperature, acting as a stabilizing agent.
• An in vitro study showing short peptides including bronchogen influence tobacco plant cell culture growth at very low concentrations.
• An in vitro study reporting that certain short peptides increase differentiation markers in human embryonic fibroblasts, hinting at geroprotective potential.
• An in vitro study demonstrating that short bioactive peptides enter animal cell nuclei and interact with DNA and RNA.
• An animal study in which a one-month course of bronchogen reversed COPD-related structural damage in rats, restoring bronchial epithelium immune and barrier function.

Dosage and effectiveness

A typical protocol is 1-2 capsules daily for 10-30 days, often run in cycles with breaks between courses. Effectiveness claims rest largely on Russian-sourced research; benefits are described as gradual and subtle, with most reports concerning chronic respiratory conditions.

Availability

Bronchogen is sold mainly by Russian peptide suppliers, with some international nootropic vendors also carrying it.